HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National surgical adjuvant breast and bowel project protocol B-15

Journal of the National Cancer Institute

Volumn 92, Issue 24, 2000, Pages 1991-1998

  Paik, Soonmyung ^a,c   Bryant, John ^b   Tan Chiu, Elizabeth ^c   Yothers, Greg ^b   Park, Chanheun ^a   Wickerham, D Lawrence ^c   Wolmark, Norman ^c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; TISSUE SECTION; TREATMENT FAILURE;

EID: 0034694659     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.24.1991     Document Type: Article

References (13)

1. Adjuvant systemic therapy for women with node-positive breast cancer
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
4. Project ChemoInsight reveals physician practice patterns for adjuvant breast cancer chemotherapy, and compares the dose intensity of CMF, AC, and CAF
5. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?
6. Should HER2 status be routinely measured for all breast cancer patients?
7. Using HER2 to choose chemotherapy in breast cancer: Is it ready for the clinic?
8. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
9. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
10. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
11. Prognostic importance of c-erbB-2 expression in breast cancer
12. Effect of c-erbB-2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
13. Benefits of CMF treatment in lymph node-positive breast cancer overexpressing HER2